Seres Therapeutics (MCRB) Tops Q3 EPS by 4c

Seres Therapeutics (NASDAQ: MCRB) reported Q3 EPS of ($0.46), $0.04 better than the analyst estimate of ($0.50). Revenue for the quarter came in at $13.02 million versus the consensus estimate of $10.38 million.

For earnings history and earnings-related data on Seres Therapeutics (MCRB) click here.

You May Also Be Interested In

• EU proposes to curb Airbnb and short-term rentals amid housing shortage
• Geberit AG (GEBN:SW) (GBERY) PT Raised to CHF712 at Jefferies
• Ardent Health revises 2025 non-GAAP figures after SEC staff talks